Abstract
Background: The capsaicin receptor TRPV1 is a polymodal nociceptor expressed predominantly on sensory neurons. Pharmacological blockade of TRPV1 by antagonists and desensitization of TRPV1 by agonists represent alternative therapeutic strategies for the treatment of various medical conditions, including chronic pain. Objectives and methods: A vast patent literature (> 1,000 patents) disclosing both natural and synthetic molecules as TRPV1 agonist and antagonist exists. A comprehensive review of the TRPV patent literature is out of the scope of this paper. Instead, it focuses on recent advances in the potential use of TRPV1 agonists and antagonists for therapeutic purposes. In particular, this review attempts to collate these patents according to the chemical classes they disclose and discusses the structure–activity relationships that best bring out their therapeutic potential. Results/conclusion: A wide range of TRPV1 drug formulations (per os, topical and site-specific injectable) is expected to enter the clinical practice for indications as wide as chronic pain, overactive bladder, chronic cough, obesity, diabetes and, possibly, cancer as well as neurological and psychiatric disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
